Results from the Phase 2 COG1201 SHIMMER study of zervimesine in dementia with Lewy bodies (DLB) were presented at the Alzheimer’s Association International Conference. The study showed a positive impact on neuropsychiatric, cognitive, motor, and functional scales, with DLB patients treated with zervimesine scoring 86% better on the neuropsychiatric inventory compared to placebo. Additionally, the Phase 2 COG0201 SHINE study of zervimesine in Alzheimer’s disease demonstrated a more robust response in participants with lower levels of p-tau217, showing significant improvements in cognitive function. Biomarker evidence supports zervimesine’s impact on Alzheimer’s disease biology.

Zervimesine (CT1812) is an investigational drug being developed by Cognition Therapeutics, Inc. for the treatment of CNS diseases such as Alzheimer’s disease and dementia with Lewy bodies (DLB). The drug has shown positive results in clinical studies, with significant improvements in behavioral symptoms and cognitive function in patients. Zervimesine has been granted FDA Fast Track designation in Alzheimer’s disease and has been generally well tolerated in clinical trials. The USAN Council has adopted zervimesine as the United States Adopted Name for CT1812. Cognition Therapeutics is focused on developing innovative therapies for age-related degenerative disorders of the central nervous system and retina.

Read more at GlobeNewswire: Cognition Therapeutics Presents Data at AAIC Highlighting